22ND CENTURY GROUP INC

XXIINASDAQ

🏆 #4097 by market capEarnings Aug 12US Equity

$745.90▼ $30.88 (−4.14%)

Simulated price

1h—

24h▼ 4.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$1M

Small Cap

📈Revenue Growth (YoY)

-34.1%

Declining

📊Gross Margin

-20.1%

Thin

💵FCF Margin

—

⚖️P/S Ratio

0.1x

Cheap

Otter Score

Weak

No chart data available for XXII.

Trading Snapshot

Day Range: $737.40 – $750.06
52-Week Range: $3.61 – $801.00
Volume: $3.90B
Avg Volume: $2.80B
Shares Outstanding: 350,000
Next Earnings: Oct 11, 2026

Fundamentals Snapshot

Annual Revenue: $7M
Last Q Revenue: $4M
P/E Ratio: —
P/S Ratio: 0.1x
EPS (TTM): $33.51
Dividend Yield: —

Why Investors Own XXII

✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$7M▲ +55.1% YoY

Gross Margin (TTM)

62.3%▼ −0.2% YoY

Operating Income (TTM)

$563,920▲ +55.1% YoY

Free Cash Flow (TTM)

$944,566▲ +55.1% YoY

About 22ND CENTURY GROUP INC

22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.

🦦